Get the Stockscreener App
2.23
3.72%
0.08
After Hours:
2.25
0.02
+0.90%
Aditxt Inc stock is traded at $2.23, with a volume of 104.23K.
It is up +3.72% in the last 24 hours and down -55.40% over the past month.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.
See More
Previous Close:
$2.15
Open:
$2.15
24h Volume:
104.23K
Relative Volume:
0.04
Market Cap:
$2.78M
Revenue:
$212.10K
Net Income/Loss:
$-40.19M
P/E Ratio:
-0.00042
EPS:
-5313.2836
Net Cash Flow:
$-13.92M
1W Performance:
-3.04%
1M Performance:
-55.40%
6M Performance:
-98.32%
1Y Performance:
-99.99%
1-Day Range:
$2.13
$2.27
1-Week Range:
$2.05
$2.33
52-Week Range:
$2.04
$27,200.00
Aditxt Inc Stock (ADTX) Company Profile
Name
Aditxt Inc
Sector
Industry
Phone
909-488-0844
Address
737 N. FIFTH STREET, SUITE 200, RICHMOND
Compare ADTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADTX
Aditxt Inc
|
2.23 | 2.78M | 212.10K | -40.19M | -13.92M | -5,313.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Aditxt Inc Stock (ADTX) Latest News
Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, - GuruFocus
Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™ - Eagle-Tribune
Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department - GuruFocus
Aditxt secures $256K through senior note sales By Investing.com - Investing.com Nigeria
Aditxt secures $256K through senior note sales - Investing.com
Aditxt’s Subsidiary Pearsanta Gets IRB Approval - TipRanks
Aditxt Delivers Shareholder Update and 2024 Year-End Plan - ADVFN
Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™ - Quantisnow
Pre-market Movers: RGC, SYRS, ADTX, ATXI... - RTTNews
Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adim - GuruFocus
Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune™ - Business Wire
Dr. Charles Howe of the Mayo Clinic’s Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt’s Subsidiary Adimune - Bluefield Daily Telegraph
Aditx Therapeutics Stock Hits 52-Week Low at $2.35 By Investing.com - Investing.com South Africa
Aditx Therapeutics Stock Hits 52-Week Low at $2.35 - Investing.com Australia
Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025 | ADTX Stock News - GuruFocus
Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025 - Business Wire
Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Cl - GuruFocus
Aditxt (ADTX) Study Reinforces ADI-100's Promise in Autoimmune T - GuruFocus
Aditxt Subsidiary Adimune Announces Positive Results from Mayo C - GuruFocus
Aditxt Regains Nasdaq Compliance with Bid Price - TipRanks
Aditxt announces results from ADI-100 study - TipRanks
Aditxt Subsidiary Adimune Announces Positive Results From Mayo Clinic Pre-Clinical Studies To Support FDA And European Regulatory Submissions For Type 1 Diabetes, Psoriasis, And Stiff Person Syndrome Human Trials - marketscreener.com
Aditxt (ADTX) Study Reinforces ADI-100's Promise in Autoimmune Treatments | ADTX Stock News - GuruFocus
Evofem Biosciences to Present at Emerging Growth Conference - Quantisnow
Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials - Business Wire
Rhythm Pharmaceuticals (RYTM): Surge in Interest Following Positive Trial Results | ADTX Stock News - GuruFocus
Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements | ADTX Stock News - GuruFocus
ADITXT Earnings Preview: Recent $ADTX Insider Trading, Hedge Fund Activity, and More - Nasdaq
Aditxt regains Nasdaq compliance, updates on operations By Investing.com - Investing.com India
Aditxt Weekly Update to Highlight Recent Events, Including Regai - GuruFocus
Aditxt regains Nasdaq compliance, updates on operations - Investing.com
Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements - Business Wire
Why Aditxt Inc. (ADTX) Went Down On Thursday? - Insider Monkey
Aditxt invests $1.5 million in Evofem amid merger talks By Investing.com - Investing.com India
10 Stocks Fall Behind Amid Market Optimism - Insider Monkey
Aditxt Enters Securities Purchase Agreement With Evofem BiosciencesSEC Filing - marketscreener.com
Is Aditxt Shares’ Steep Decline a Buying Opportunity? - timothysykes.com
Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listi - GuruFocus
Aditxt regains Nasdaq compliance, cancels hearing By Investing.com - Investing.com India
Aditxt regains Nasdaq compliance, cancels hearing - Investing.com
Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements - Bluefield Daily Telegraph
Aditx Therapeutics stock hits 52-week low at $4 amid steep decline By Investing.com - Investing.com South Africa
Aditxt, Inc. Discusses Appili Therapeutics Acquisition Plans - TipRanks
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Aditx Therapeutics stock hits 52-week low at $4 amid steep decline - Investing.com India
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Appili President And CEO, Don Cilla To Join Aditxt CEO, Amro Albanna For Aditxt Weekly Update On April 4, 2025 - MarketScreener
Appili Therapeutics CEO to Discuss Strategic Growth and Funding Initiatives - TipRanks
Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025 - The Manila Times
Aditxt Inc Stock (ADTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
2.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):